Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in
lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its …

Atherosclerosis is a chronic vascular inflammatory disease associated to oxidative stress
and endothelial dysfunction. Oxidation of low‐density lipoprotein (LDL) cholesterol is one of …

It is now about 20 years since the first case of a gain-of-function mutation involving the as-yet-
unknown actor in cholesterol homeostasis, proprotein convertase subtilisin/kexin type 9 …

Background: Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (i) are a class
of lipid-lowering drugs suggested to hold a plethora of beneficial effects independent of their …

Importance Lipid pathways have been implicated in the pathogenesis of psoriasis, and
some lipid-lowering drugs, such as statins, are hypothesized to have disease-modifying …

Background The intensity of inflammation during COVID-19 is related to adverse outcomes.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in low-density lipoprotein …

Proprotein convertase subtilisin/kexin type 9 (PCSK9), mainly synthetized and released by
the liver, represents one of the key regulators of low-density lipoprotein cholesterol …

Abstract annually in Europe, 4 million people die from cardiovascular diseases, the main
cause of which is atherosclerosis. In order to slow down the development of atherosclerotic …

Background: Activated macrophages contribute to the pathogenesis of vascular disease.
Vein graft failure is a major clinical problem with limited therapeutic options. PCSK9 …

Characterized as a chronic inflammatory disease of the large arteries, atherosclerosis is the
primary cause of cardiovascular disease, the leading contributor of morbidity and mortality …